Tags

Type your tag names separated by a space and hit enter

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Int J Antimicrob Agents. 2020 May; 55(5):105954.IJ

Abstract

Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. Therefore, treatment of the cytokine storm has become an important part of rescuing severe COVID-19 patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19.

Authors+Show Affiliations

Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China.Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China; The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: zhaohong_pufh@bjmu.edu.cn.Department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, China; The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China; Peking University International Hospital, Beijing, China. Electronic address: john131212@sina.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32234467

Citation

Zhang, Chi, et al. "Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality." International Journal of Antimicrobial Agents, vol. 55, no. 5, 2020, p. 105954.
Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
Zhang, C., Wu, Z., Li, J. W., Zhao, H., & Wang, G. Q. (2020). Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International Journal of Antimicrobial Agents, 55(5), 105954. https://doi.org/10.1016/j.ijantimicag.2020.105954
Zhang C, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020;55(5):105954. PubMed PMID: 32234467.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. AU - Zhang,Chi, AU - Wu,Zhao, AU - Li,Jia-Wen, AU - Zhao,Hong, AU - Wang,Gui-Qiang, Y1 - 2020/03/29/ PY - 2020/02/26/received PY - 2020/03/14/revised PY - 2020/03/19/accepted PY - 2020/4/3/pubmed PY - 2020/5/29/medline PY - 2020/4/3/entrez KW - COVID-19 KW - Cytokine release syndrome KW - IL-6 KW - IL-6R KW - Tocilizumab SP - 105954 EP - 105954 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 55 IS - 5 N2 - Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is an important cause of death. Therefore, treatment of the cytokine storm has become an important part of rescuing severe COVID-19 patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients. Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32234467/Cytokine_release_syndrome_in_severe_COVID_19:_interleukin_6_receptor_antagonist_tocilizumab_may_be_the_key_to_reduce_mortality_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(20)30104-7 DB - PRIME DP - Unbound Medicine ER -